Euroviews: Europe’s Challenge in Bridging Scientific Excellence and Commercial Success
Euroviews Why Europe struggles to turn – A striking contradiction defines Europe’s current landscape. While the continent consistently produces groundbreaking scientific research, it often fails to translate that innovation into thriving global enterprises. The issue is not just about science itself, but about the systems that enable it to evolve into practical, market-driven solutions. Despite nurturing highly skilled researchers and forward-thinking entrepreneurs, many of these individuals choose to relocate their ambitions overseas, where the environment for growth appears more conducive. This trend is particularly pronounced in the health and life sciences sector, where Europe’s scientific foundation remains robust, yet its ability to scale and commercialize breakthroughs lags behind.
The European Commission’s Report on the Biotech Industry
The European Commission has identified a clear issue in its 2025 Biotech Act. According to the document, the process of financing and scaling innovations is increasingly shifting to other regions, leaving Europe at a disadvantage. From 2015 to June 2025, U.S. biopharma startups attracted approximately €219 billion in venture capital investment focused on health biotechnology. In contrast, their European counterparts secured only €25 billion, a sum that is roughly nine times smaller. This disparity underscores a critical challenge: Europe’s scientific output is not being matched by the financial backing necessary to transform ideas into profitable ventures.
The gap is equally evident in the medical testing sector. Between 2013 and 2023, the European Economic Area’s share of global clinical trials dropped from 18% to 9%, while China’s share surged from under 10% to nearly 30%. This shift highlights a growing imbalance in the distribution of innovation and investment. Meanwhile, the introduction of new treatments also reveals a pattern: American patients often receive therapies before their European counterparts. Even after approval, the fragmented market within Europe leads to uneven access, with some member states lagging behind in the delivery of advanced medical care.
Why the Fragmentation Matters
Europe’s inability to harness its scientific potential is tied to the complexity of its economic structure. The continent’s divided market creates barriers that hinder the rapid scaling of innovations. For example, a medicine approved in one country may take months to reach patients in another, due to differing regulatory processes and healthcare systems. This fragmentation not only slows down the adoption of new treatments but also reduces the overall efficiency of the continent’s innovation ecosystem.
“We love Europe, but if we want to grow, we have to leave,”
repeated repeatedly during the preparation of my report on the future of the Single Market. These words from young entrepreneurs capture the essence of the problem. They are drawn to Europe’s intellectual environment, yet the lack of financial and logistical support compels them to seek opportunities elsewhere. This exodus of talent signals a deeper issue: Europe is not just losing its innovators, but also its capacity to compete in the global race for technological leadership.
The Fifth Freedom: A Vision for Unity
Recognizing this challenge, I proposed the concept of a Fifth Freedom, building on the existing four pillars of the Single Market—free movement of goods, services, capital, and people. The idea is to create a seamless flow of knowledge, research, and innovation across Europe. This would allow a startup in Lisbon to connect with investors in Paris, collaborate with scientists in Warsaw, and establish a production site in Milan without the need to cross international borders. Such integration could transform Europe into a cohesive hub for innovation, fostering collaboration and reducing the hurdles that drive talent and investment abroad.
The health sector exemplifies both the problem and the potential for a solution. Europe’s public health systems hold vast reserves of medical knowledge, making it a prime candidate for leading the medicine of the future. However, this potential is unrealized due to fragmented systems and inconsistent policies. If Europe can overcome these obstacles, it could position itself as a global leader in health innovation. The key lies in connecting its scientific strengths with a unified market that supports the entire lifecycle of a product—from research to commercialization.
Global Competitors and the Need for Strategy
The competition is fierce. The United States, with its deep pools of capital and vast internal market, has established a culture that rewards bold ideas almost immediately. Meanwhile, China is investing heavily in both scientific discovery and its commercialization, creating a dual engine of innovation. As leaders on both sides of the Atlantic advocate for ‘reshoring’ industries, Europe must ask itself a crucial question: reshoring to what? Without a robust, scalable market, no amount of strategic planning can reverse the trend of companies leaving the continent.
Europe’s scientific prowess is undeniable, but the lack of a cohesive economic framework is holding it back. The continent generates cutting-edge research, yet it struggles to convert that research into viable businesses. This disconnect is not just a matter of funding, but also of infrastructure, policy alignment, and cultural attitudes toward risk-taking. The current system rewards invention but often fails to sustain it. The result is a cycle where Europe remains a source of ideas, but not a destination for growth.
Towards a Unified Future
Addressing this issue requires a fundamental shift in how Europe approaches innovation and entrepreneurship. The Fifth Freedom represents a step in the right direction, but it must be supported by concrete actions. Policymakers need to prioritize the creation of a single, open market for health technologies that eliminates regulatory silos and streamlines the approval process. This would ensure that breakthroughs reach patients faster and more equitably, reinforcing Europe’s position as a leader in health innovation.
Moreover, Europe must cultivate an environment that encourages risk-taking and long-term investment. The current reliance on short-term financing often forces startups to seek funding in more dynamic markets. By fostering a culture of patience and strategic vision, Europe can retain its brightest minds and turn them into commercial success stories. The challenge is not just about science, but about aligning the continent’s resources and ambitions to create a sustainable ecosystem for innovation.
A Call to Action
Europe cannot afford to remain a passive observer in the global race for innovation. The next generation of biotech founders should be able to build their companies, secure funding, and deliver treatments to patients without leaving the continent. This requires a collective effort to bridge the gap between research and business. By embracing the Fifth Freedom and investing in a unified market, Europe can transform its scientific potential into a competitive advantage. The question is no longer whether Europe can become a global leader in innovation—it is whether it will act decisively to make it happen.
As the 21st century unfolds, the success of nations will be determined by their ability to scale ideas quickly. The United States and China have already demonstrated how this can be achieved, but Europe has the unique opportunity to lead by example. It must leverage its scientific strengths, unify its markets, and create an environment where innovation is not just possible, but profitable. Only then can the continent fulfill its promise and secure its place in the global economy of the future.
